Research programme: RNA interference-based therapeutics - Celera/Merck

Drug Profile

Research programme: RNA interference-based therapeutics - Celera/Merck

Latest Information Update: 29 Jul 2010

Price : $50

At a glance

  • Originator Celera Diagnostics
  • Developer Merck & Co
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 29 Jul 2010 Discontinued for Cancer in USA (Parenteral)
  • 10 Apr 2008 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top